India approves first dengue vaccine for individuals aged 4 to 60 years
The Central Drugs Standard Control Organisation (CDSCO), through the Drug Controller General of India (DCGI), granted marketing authorisation to Takeda's QDENGA (TAK-003) as India's first approved dengue vaccine
The vaccine is approved for individuals aged 4 to 60 years and can be administered without prior dengue screening or serostatus testing
QDENGA is designed to protect against all four dengue virus serotypes (DENV-1, 2, 3, and 4)
The approval followed a comprehensive scientific evaluation of quality, safety, and efficacy under the Drugs and Cosmetics Act, 1940 and the Drugs Rules, 1945, including a Phase III study conducted in the Indian population
Dengue Virus Serotypes and Vaccine Design
Dengue is caused by four distinct virus serotypes (DENV-1 to DENV-4), all of which circulate in India. Infection with one serotype provides lifelong immunity to that serotype but only short-term cross-protection against the others; a subsequent infection with a different serotype carries a higher risk of severe dengue due to antibody-dependent enhancement (ADE) — making a vaccine that protects against all four serotypes simultaneously (tetravalent) essential.
Key Details
- QDENGA is a live-attenuated, chimeric tetravalent vaccine built on a DENV-2 backbone; genes for the surface proteins (prM and E) of DENV-1, DENV-3, and DENV-4 are substituted onto that backbone to create immunogenic strains for all four serotypes
- Antibody-dependent enhancement (ADE) is the phenomenon by which pre-existing antibodies from a first dengue infection can worsen a second infection with a different serotype — the central biological challenge in dengue vaccine design
- All four DENV serotypes are known to circulate in India, with the dominant serotype shifting by region and over time
QDENGA's tetravalent, single-dose-schedule design directly addresses the ADE risk that hampered earlier dengue vaccines, which is why it can be given without pre-screening for prior dengue exposure.
Dengvaxia vs QDENGA — Why Serostatus Screening Matters
Sanofi's Dengvaxia, the first dengue vaccine developed globally, was found to increase the risk of severe dengue in people who had never been infected before (seronegative individuals), forcing WHO to restrict its use to seropositive people only. QDENGA's approval without a screening requirement marks a technical advance over this precedent.
Key Details
- Post-licensure data showed Dengvaxia recipients who were seronegative at baseline had an elevated relative risk of hospitalised, virologically confirmed dengue compared to unvaccinated seronegative individuals
- WHO's Global Advisory Committee on Vaccine Safety subsequently recommended Dengvaxia only for individuals with confirmed prior dengue infection
- QDENGA, by contrast, uses a design that permits safe administration to dengue-naive (never previously infected) individuals, removing the need for pre-vaccination testing
The explicit mention that QDENGA can be given "without prior dengue screening" is significant precisely because it corrects the seronegative-risk problem that limited the earlier Dengvaxia vaccine's rollout.
Drug Approval Pathway in India — CDSCO and DCGI
The approval was granted by CDSCO under the Ministry of Health and Family Welfare, headed by the Drug Controller General of India (DCGI), which is India's central drug regulatory authority for new drugs, vaccines, and clinical trials.
Key Details
- CDSCO functions under the Drugs and Cosmetics Act, 1940 and the Drugs Rules, 1945, and more specifically new drug/vaccine approvals follow the New Drugs and Clinical Trials Rules, 2019
- Import and marketing of a foreign-manufactured vaccine (QDENGA is manufactured by Takeda in Germany) requires CDSCO's import licence and marketing authorisation, distinct from domestic manufacturing licences issued by State Licensing Authorities
- QDENGA had already been approved in over 40 countries and received WHO prequalification before the Indian approval, which is typical for vaccines seeking Indian market entry — but Indian approval still required a India-specific Phase III bridging study
The DCGI's approval of QDENGA illustrates the standard pathway by which a globally-approved vaccine enters the Indian market — through CDSCO evaluation plus a mandatory local clinical trial component, rather than automatic recognition of foreign approvals.
- QDENGA (TAK-003) is approved in India for ages 4-60 years, without prior dengue screening
- It protects against all four dengue serotypes: DENV-1, DENV-2, DENV-3, DENV-4
- Global clinical trial data cited for QDENGA: approximately 80% efficacy against confirmed dengue at 12 months, and over 84% efficacy against hospitalisation over extended follow-up
- QDENGA is manufactured by Takeda (Germany) and had prior approval in 40+ countries plus WHO prequalification before Indian approval
- India accounts for a substantial share of the global dengue disease burden
- Dengvaxia (Sanofi), the earlier dengue vaccine, remains restricted to individuals with confirmed prior dengue infection due to elevated severe-dengue risk in seronegative recipients